At the ongoing meeting of the American Chemical Society in Denver, F. Hoffmann-La Roche Ltd. has reported the discovery of an orally available and brain-penetrant irreversible asparagine-specific endopeptidase (AEP) inhibitor, RO-7542742, for the potential treatment of neurodegenerative diseases.